Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. These updates
provide information on experimental drugs and at times give an
insight into the commercial potential of the candidate once it is
successfully developed and commercialized.
Pluristem Therapeutics, Inc
) develops placenta-based cell therapies in collaboration with
) or through research and clinical institutions. The cells from
placenta are derived using the company's proprietary PluriX
therapy and are known as PLX cells.
Pluristem intends to develop and produce cell therapy products
for the treatment of multiple disorders using several methods of
Pluristem recently announced that it has submitted its
application to the U.S. Food and Drug Administration (FDA) to
grant orphan drug designation to its PLacental eXpanded (PLX-PAD)
cells for the treatment of severe preeclampsia.
We note that Pluristem's PLX cells already enjoys orphan drug
designation in the U.S. for the treatment of aplastic anemia and
The orphan drug designation will not only accelerate the
development of PLX cells but will also benefit Pluristem in
various stages of drug development, including faster approval
process, seven years of marketing exclusivity following marketing
approval and tax credits on certain clinical trials in the
We are encouraged by Pluristem's efforts to develop PLX cells
for various diseases.
Pluristem currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the same sector include
Biogen Idec Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).
ALEXION PHARMA (ALXN): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
PLURISTEM THERA (PSTI): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.